Novartis Reports post-marketing Data for Tofersen in Multiple sclerosis

Novartis today announced post-marketing results for tofersen in patients with multiple sclerosis. The study demonstrated that tofersen reduces disease progression risk compared to standard of care or placebo. These results provide important insights into the treatment of multiple sclerosis and support the continued development of tofersen in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.